<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34588611</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1530-0447</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>91</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pediatric research</Title>
          <ISOAbbreviation>Pediatr Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Severity of neonatal opioid withdrawal syndrome with prenatal exposure to serotonin reuptake inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>867</StartPage>
          <EndPage>873</EndPage>
          <MedlinePgn>867-873</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41390-021-01756-4</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">To evaluate the severity of neonatal opioid withdrawal syndrome (NOWS) in infants prenatally exposed to medications for opioid use disorder (MOUD) and serotonin reuptake inhibitors (SRI).</AbstractText>
          <AbstractText Label="METHODS">A prospective cohort included 148 maternal-infant pairs categorized into MOUD (n = 127) and MOUD + SRI (n = 27) groups. NOWS severity was operationalized as the infant's need for pharmacologic treatment with opioids, duration of hospitalization, and duration of treatment. The association between prenatal SRI exposure and the need for pharmacologic treatment (logistic regression), time-to-discharge, and time-to-treatment discontinuation (Cox proportional hazards modeling) was examined after adjusting for the type of maternal MOUD, use of hydroxyzine, other opioids, benzodiazepines/sedatives, alcohol, tobacco, marijuana, gestational age, and breastfeeding.</AbstractText>
          <AbstractText Label="RESULTS">Infants in the MOUD + SRI group were more likely to receive pharmacologic treatment for NOWS (OR = 3.58; 95% CI: 1.31; 9.76) and had a longer hospitalization (median: 11 vs. 6 days; HR = 0.54; 95% CI: 0.33; 0.89) compared to the MOUD group. With respect to time-to-treatment discontinuation, no association was observed in infants who received treatment (HR = 0.59; 95% CI: 0.26, 1.32); however, significant differences were observed in the entire sample (HR = 0.55; 95% CI: 0.34, 0.89).</AbstractText>
          <AbstractText Label="CONCLUSIONS">Use of SRIs among pregnant women on MOUD might be associated with more severe NOWS.</AbstractText>
          <AbstractText Label="IMPACT">A potential drug-drug interaction between maternal SRIs and opioid medications that inhibit the reuptake of serotonin has been hypothesized but not carefully evaluated in clinical studies. Results of this prospective cohort indicate that the use of SRIs among pregnant women on MOUD is associated with more severe neonatal opioid withdrawal syndrome. This is the first prospective study which carefully examined effect modification between the type of maternal MOUD and SRI use on neonatal outcomes. This report lays the foundation for treatment optimization in pregnant women with co-occurring mental health and substance use disorders.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bakhireva</LastName>
            <ForeName>Ludmila N</ForeName>
            <Initials>LN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice and Administrative Sciences, Substance Use Research and Education (SURE) Center, College of Pharmacy, University of New Mexico, NM, albuquerque, USA. lbakhireva@salud.unm.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Family and Community Medicine, School of Medicine, University of New Mexico, NM, albuquerque, USA. lbakhireva@salud.unm.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Epidemiology, Biostatistics and Preventive Medicine, Department of Internal Medicine, School of Medicine, University of New Mexico, NM, albuquerque, USA. lbakhireva@salud.unm.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sparks</LastName>
            <ForeName>Aydan</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice and Administrative Sciences, Substance Use Research and Education (SURE) Center, College of Pharmacy, University of New Mexico, NM, albuquerque, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herman</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of New Mexico Hospital, NM, albuquerque, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hund</LastName>
            <ForeName>Lauren</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Law, University of New Mexico, NM, albuquerque, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ashley</LastName>
            <ForeName>Malia</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of New Mexico Hospital, NM, albuquerque, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, School of Medicine, University of New Mexico, NM, albuquerque, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Salisbury</LastName>
            <ForeName>Amy</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>School of Nursing, Virginia Commonwealth University, Richmond, VA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AA021771</GrantID>
            <Acronym>AA</Acronym>
            <Agency>NIAAA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R34 DA050237</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Pediatr Res</MedlineTA>
        <NlmUniqueID>0100714</NlmUniqueID>
        <ISSNLinking>0031-3998</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Pediatr Res. 2022 Mar;91(4):727-728</RefSource>
          <PMID Version="1">34815528</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007232" MajorTopicYN="Y">Infant, Newborn, Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009357" MajorTopicYN="Y">Neonatal Abstinence Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009293" MajorTopicYN="Y">Opioid-Related Disorders</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011297" MajorTopicYN="Y">Prenatal Exposure Delayed Effects</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="Y">Substance Withdrawal Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>30</Day>
          <Hour>7</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34588611</ArticleId>
        <ArticleId IdType="doi">10.1038/s41390-021-01756-4</ArticleId>
        <ArticleId IdType="pii">10.1038/s41390-021-01756-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Krebs, E. et al. Cost-effectiveness of publicly funded treatment of opioid use disorder in California. Ann. Intern. Med. 168, 10–19 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29159398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ko, J. Y. et al. Vital signs: prescription opioid pain reliever use during pregnancy—34 U.S. jurisdictions, 2019. Morb. Mortal. Wkly Rep. 69, 897–903 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Desai, R. J., Hernandez-Diaz, S., Bateman, B. T. &amp; Huybrechts, K. F. Increase in prescription opioid use during pregnancy among medicaid-enrolled women. Obstet. Gynecol. 123, 997–1002 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24785852</ArticleId>
            <ArticleId IdType="pmc">4020039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patrick, S. W. et al. Prescription opioid epidemic and infant outcomes. Pediatrics 135, 842–850 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25869370</ArticleId>
            <ArticleId IdType="pmc">4411781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haight, S. C., Ko, J. Y., Tong, V. T., Bohm, M. K. &amp; Callaghan, W. M. Opioid use disorder documented at delivery hospitalization—United States, 1999-2014. Morb. Mortal. Wkly Rep. 67, 845–849 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Mortensen, N. P., Caffaro, M. M., Snyder, R. W., Yueh, Y. L. &amp; Fennell, T. R. Placental trophoblast transfer of opioids following exposures to individual or mixtures of opioids in vitro. Exp. Biol. Med. (Maywood) 244, 846–849 (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Nekhayeva, I. A. et al. Bidirectional transfer of methadone across human placenta. Biochem. Pharmacol. 69, 187–197 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15588727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jansson, L. M. &amp; Patrick, S. W. Neonatal abstinence syndrome. Pediatr. Clin. North. Am. 66, 353–367 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30819342</ArticleId>
            <ArticleId IdType="pmc">7605356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doberczak, T. M., Kandall, S. R. &amp; Friedmann, P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet. Gynecol. 81, 936–940 (1993).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8497359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuschel, C. A., Austerberry, L., Cornwell, M., Couch, R. &amp; Rowley, R. S. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch. Dis. Child Fetal Neonatal Ed. 89, 390–393 (2004).</Citation>
        </Reference>
        <Reference>
          <Citation>Patrick, S. W. et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 307, 1934–1940 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22546608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winkelman, T. N. A., Villapiano, N., Kozhimannil, K. B., Davis, M. M. &amp; Patrick, S. W. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014. Pediatrics 141, e20173520 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29572288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jansson, L. M., Velez, M., &amp; Harrow, C. The opioid-exposed newborn: assessment and pharmacologic management. J. Opioid Manag. 5, 47–55 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19344048</ArticleId>
            <ArticleId IdType="pmc">2729086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bagley, S. M., Wachman, E. M., Holland, E. &amp; Brogly, S. B. Review of the assessment and management of neonatal abstinence syndrome. Addict. Sci. Clin. Pract. 9, 19 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25199822</ArticleId>
            <ArticleId IdType="pmc">4166410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huybrechts, K. F. et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ 358, 3326 (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Kaltenbach, K. et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction 107, 45–52 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23106926</ArticleId>
            <ArticleId IdType="pmc">4268864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charles, M. K. et al. Male sex associated with increased risk of neonatal abstinence syndrome. Hosp. Pediatr. 7, 328–334 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28465360</ArticleId>
            <ArticleId IdType="pmc">5519405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ACOG. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists Number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet. Gynecol. 111, 1001–1020 (2008).</Citation>
        </Reference>
        <Reference>
          <Citation>Molenaar, N. M. et al. The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability. J. Affect. Disord. 264, 82–89 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31846905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moses-Kolko, E. L. et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293, 2372–2383 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15900008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salisbury, A. L. et al. The roles of maternal depression, serotonin reuptake inhibitor treatment, and concomitant benzodiazepine use on infant neurobehavioral functioning over the first postnatal month. Am. J. Psychiatry 173, 147–157 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26514656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ter Horst, P. G. J. et al. Clomipramine concentration and withdrawal symptoms in 10 neonates. Br. J. Clin. Pharm. 73, 295–302 (2012).</Citation>
        </Reference>
        <Reference>
          <Citation>Anderson, G. M., Czarkowski, K., Ravski, N. &amp; Epperson, C. N. Platelet serotonin in newborns and infants: ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors. Pediatr. Res. 56, 418–422 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15240861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laine, K., Heikkinen, T., Ekblad, U. &amp; Kero, P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 60, 720–726 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12860776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakhireva, L. N., Lowe, J. R., Gutierrez, H. L. &amp; Stephen, J. M. Ethanol, Neurodevelopment, Infant and Child Health (ENRICH) prospective cohort: study design considerations. Adv. Pediatr. Res. 2, e20150428 (2015).</Citation>
        </Reference>
        <Reference>
          <Citation>Finnegan, L. P., Connaughton, J. F. Jr., Kron, R. E. &amp; Em-ich, J. P. Neonatal abstinence syndrome: assessment and management. Addict. Dis. 2, 141–158 (1975).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1163358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leeman, L. M. et al. Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates. J. Matern. Fetal Neonatal Med. 24, 955–959 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21142769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Hashimi, M., Scott, S. W., Thompson, J. P. &amp; Lambert, D. G. Opioids and immune modulation: more questions than answers. Br. J. Anaesth. 111, 80–88 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23794649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gopman, S. Prenatal and postpartum care of women with substance use disorders. Obstet. Gynecol. Clin. North. Am. 41, 213–228 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24845486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreitinger, C. et al. The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment. J. Matern. Fetal Neonatal Med. 29, 783–788 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25758627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaltenbach, K. et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug Alcohol Depend. 185, 40–49 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29413437</ArticleId>
            <ArticleId IdType="pmc">5906792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobson, S. W., Chiodo, L. M., Sokol, R. J. &amp; Jacobson, J. L. Validity of maternal report of prenatal alcohol, cocaine, and smoking in relation to neurobehavioral outcome. Pediatrics 109, 815–825 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11986441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowman, R. S., Stein, L. I. &amp; Newton, J. R. Measurement and interpretation of drinking behavior: I. On measuring patterns of alcohol consumption: II. Relationships between drinking behavior and social adjustment in a sample of problem drinkers. J. Stud. Alcohol. 36, 1154–1172 (1975).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">240971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>United States Department of Health Human Services: Substance Abuse Mental Health Services Administration, Center for Behavioral Health Statistics Quality. National Survey on Drug Use and Health, 2011, v. 2015. https://doi.org/10.3886/ICPSR34481.v4 .</Citation>
        </Reference>
        <Reference>
          <Citation>VanderWeele, T. J., Mumford, S. L. &amp; Schisterman, E. F. Conditioning on intermediates in perinatal epidemiology. Epidemiology 23, 1–9 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22157298</ArticleId>
            <ArticleId IdType="pmc">3240847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatt-Mehta, V., Richards, J., Sturza, J. &amp; Schumacher, R. E. Impact of in-utero exposure to selective serotonin reuptake inhibitors and opioids on neonatal opioid withdrawal syndrome. J. Addict. Med. 13, 227–234 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30489344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seligman, N. S. et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am. J. Obstet. Gynecol. 199, 1–7 (2008).</Citation>
        </Reference>
        <Reference>
          <Citation>Wachman, E. M. et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J. Addict. Med. 5, 293–299 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21857233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Connor, A. B., O’Brien, L., Alto, W. A. &amp; Wong, J. Does concurrent in utero exposure to buprenorphine and antidepressant medications influence the course of neonatal abstinence syndrome? J. Matern. Fetal Neonatal Med. 29, 112–114 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25394611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones, H. E. et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 363, 2320–2331 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21142534</ArticleId>
            <ArticleId IdType="pmc">3073631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldo, B. A. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch. Toxicol. 92, 2457–2473 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29916050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemeryck, A. &amp; Belpaire, F. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr. Drug Metab. 3, 13–37 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11876575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jefferies, A. L. Selective serotonin reuptake inhibitors in pregnancy and infant outcomes. Paediatr. Child Health 16, 562–563 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23115498</ArticleId>
            <ArticleId IdType="pmc">3223895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones, C. M. &amp; McCance-Katz, E. F. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 197, 78–82 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30784952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilcox, A. J., Weinberg, C. R. &amp; Basso, O. On the pitfalls of adjusting for gestational age at birth. Am. J. Epidemiol. 174, 1062–1068 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21946386</ArticleId>
            <ArticleId IdType="pmc">3243938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ananth, C. V. &amp; Schisterman, E. F. Confounding, causality, and confusion: the role of intermediate variables in interpreting observational studies in obstetrics. Am. J. Obstet. Gynecol. 217, 167–175 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28427805</ArticleId>
            <ArticleId IdType="pmc">5545051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnaudo, C. L., Andraka-Christou, B. &amp; Allgood, K. Psychiatric co-morbidities in pregnant women with opioid use disorders: prevalence, impact, and implications for treatment. Curr. Addict. Rep. 4, 1–13 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28357191</ArticleId>
            <ArticleId IdType="pmc">5350195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ACOG. Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstet. Gynecol. 130, 81 (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Shen, Y., Lo-Ciganic, W. H., Segal, R. &amp; Goodin, A. J. Prevalence of substance use disorder and psychiatric comorbidity burden among pregnant women with opioid use disorder in a large administrative database, 2009-2014. J. Psychosom. Obstet. Gynaecol. 18, 1–7 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Yonkers, K. et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen. Hosp. Psychiatry 31, 403–413 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19703633</ArticleId>
            <ArticleId IdType="pmc">3094693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin, C. E., Scialli, A. &amp; Terplan, M. Addiction and depression: unmet treatment needs among reproductive age women. Matern. Child Health J. 24, 660–667 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32185570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shrestha, S., Roberts, M. H., Maxwell, J. R., Leeman, L. M. &amp; Bakhireva, L. N. Post-discharge healthcare utilization in infants with neonatal opioid withdrawal syndrome. Neurotoxicol. Teratol. 86, e106975 (2021).</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
